

Swedencare's subsidiary Vetio receives Intention to Grant from the European Patent Office (EPO) and Notice of Allowance from the United States Patent Office (USPTO) for its Starch-Free Soft Chew

Montreal, Quebec (June 28, 2022) Swedencare's subsidiary Vetio has received an Intention to Grant from the European Patent Office (EPO) and a Notice of Allowance from the United States Patent Office (USPTO) for its Starch-Free Soft Chew for Veterinary Applications. Vetio's Soft Chew Technology platform for Animal Health is ideally suited for delivering one or more active ingredients in a veterinary pharmaceutical-grade dosage form.

According to scientist Gueorgui Puchkarov, "Vetio's novel composition and process contains no starch and no added water, making it well suited for moisture sensitive active ingredients". Puchkarov added that "the composition of ingredients produces a texture that remains soft and malleable over time, allowing for excellent stability, bioavailability, and allows for in-vitro dissolution methods of discriminating nature as a means of quality control."

Alain Dugal, General Manager of Vetio Animal Health's Montreal pharma operations, commented "Vetio offers end-to-end CDMO services for Animal Health and has all of the tools in-house to develop and commercially manufacture the very best companion animal soft chew drug products".

Dugal added that "Vetio's soft chew is a premium delivery system, capable of delivering multiple APIs in a highly palatable matrix based on Vetio's own FlavorPal line of palatants.

About Vetio

Vetio is a Contract Development and Manufacturing Organization (CDMO) that specializes in complex drug product formulation and manufacturing of veterinary pharmaceutical, supplement, and dermatology products. Vetio is committed to the development and manufacturing of products that improve the lives of animals, while assuring the safety, quality, and compliance of our products to the highest industry standards. Vetio is a wholly-owned subsidiary of Swedencare.

For more information, please contact:

Håkan Lagerberg, CEO Swedencare
Phone: +46 (0)73 517 01 70
Email: hakan.lagerberg@swedencare.se

Jenny Graflind, CFO Swedencare
Phone: +46 (0)73 944 85 54
Email: jenny.graflind@swedencare.se

FNCA is the Certified Adviser of the Company
Phone: +46 (0) 8 528 00 399
Email: info@fnca.se

Please visit the Company homepage www.swedencare.com

About Swedencare

Swedencare, a listed company on NASDAQ First North Growth Market, specializes in pet healthcare and produces, markets and sells premium products in the global and fast-growing market. The company has a wide range of strong brands and products within most therapy areas, including Animal Pharmaceuticals®, Nutravet®, NutriScience, Pet MD®, Stratford®, VetWELL®, NaturVet® as well as ProDen PlaqueOff® for oral health to dogs and cats. Swedencare's headquarter is in Malmö, Sweden with subsidiaries located in nine countries with products sold in approximately fifty five markets. Swedencare's sales have increased significantly over the last few years with strong margins and profits.

Image Attachments

[Soft Chews](#)

Attachments

[Swedencare's subsidiary Vetio receives Intention to Grant from the European Patent Office \(EPO\) and Notice of Allowance from the United States Patent Office \(USPTO\) for its Starch-Free Soft Chew](#)